Philip N. Newsome, Arun J. Sanyal, Kristiane A. Engebretsen, Iris Kliers, Laura Østergaard, Denise Vanni, Elisabetta Bugianesi, Mary E. Rinella, Michael Roden, Vlad Ratziu
{"title":"塞马鲁肽 2.4 mg 用于代谢功能障碍相关性脂肪性肝炎患者：ESSENCE 3 期试验的基线特征和设计","authors":"Philip N. Newsome, Arun J. Sanyal, Kristiane A. Engebretsen, Iris Kliers, Laura Østergaard, Denise Vanni, Elisabetta Bugianesi, Mary E. Rinella, Michael Roden, Vlad Ratziu","doi":"10.1111/apt.18331","DOIUrl":null,"url":null,"abstract":"Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction-associated steatohepatitis (MASH).","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"66 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial\",\"authors\":\"Philip N. Newsome, Arun J. Sanyal, Kristiane A. Engebretsen, Iris Kliers, Laura Østergaard, Denise Vanni, Elisabetta Bugianesi, Mary E. Rinella, Michael Roden, Vlad Ratziu\",\"doi\":\"10.1111/apt.18331\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction-associated steatohepatitis (MASH).\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"66 1\",\"pages\":\"\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2024-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.18331\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.18331","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction-associated steatohepatitis (MASH).
期刊介绍：
Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
